After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr. Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
George Church discusses the biotechnology underpinning GRO Biosciences Inc., which could provide a workaround for some well-known problems in protein therapeutics. The startup just hauled in millions to tackle those problems.
Beyond Meat (BYND) was one of last year’s hottest stocks. Shares of the plant-based meat company exploded 859% during its first three months out of the gate.